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Abstract This randomized, double-blind study evaluated the efficacy and safety of a short, 5-day course of telithro-
mycin, a newketolide antibacterial, comparedwith a standard10-daycourse of amoxicillin/clavulanate, in the treatment
of acute exacerbations of chronic bronchitis (AECB).The study enrolled 325 adult patients with AECB and a history of
chronic obstructive pulmonarydisease (COPD).Patients received either telithromycin 800mgonce daily (qd) for 5 days
(followedbyplacebo for 5 days) or amoxicillin/clavulanate 500/125mg threetimesdaily (tid) for10 days.Clinicalcurerates
for telithromycin post-therapy (Days 17221, test-of-cure) and late post-therapy (Days 31236) were 86.1 and 78.1%,
respectively; 82.1 and 75.0% for amoxicillin/clavulanate. Excellent clinical cure rates were also observed for high-risk
patients.Bacteriologicoutcomewas satisfactory for 69.2% oftelithromycinrecipients vs 70.0% for amoxicillin/clavulanate
recipients.Both treatments were generally well tolerated, although the frequency of drug-related adverse events was
almost two-fold higher for amoxicillin/clavulanate (25.0 vs.13.1%).Thus, a 5-day course of telithromycin 800mgqd is an
effective andwell-tolerated alternativeto a standard10-daycourse of amoxicillin/clavulanate 500/125mg tid for first-line
empiric treatmentof AECB in adultswith COPD.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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The clinical course of chronic bronchitis is frequently
complicated by episodes of acute exacerbation (AECB),
leading to symptoms of increased dyspnea, chest tight-
ness, productive cough and changes in sputum color,
consistency, and amount. Among the estimated over 14
million su¡erers of chronic bronchitis in the U.S.A., one
episode of AECB is generally experienced on an annual
basis (1).Most instances ofAECB arebacterial in etiology,
with Haemophilus in£uenzae, Streptococcus pneumoniae,
and Moraxella catarrhalis frequently implicated (2).Given
that failure to treat AECB may result in progressive de-
terioration of respiratory function, prompt diagnosis
and appropriate antimicrobial treatment are important
management goals (3).Received11March 2002, accepted in revised form11March 2002
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the treatment of AECB, which is typically initiated on an
empiric basis with an agent whose spectrum of activity
encompasses the most likely causative pathogens. How-
ever, decreasing susceptibility and/or the emergence of
resistance to existing antimicrobial agents used in the
treatment of AECB are steadily increasing problems
worldwide (4). For example, the increased use of £uoro-
quinolones forAECB is associatedwith an increase in the
emergence of bacterial strains with decreased suscept-
ibility to these agents (5). Therefore, a need exists for
new antimicrobial agents that not only provide adequate
coverage of pathogens most frequently associated with
AECB, including resistant strains, but which also have a
low potential to induce, or select for, resistance.
Telithromycin (HMR 3647) is the ¢rst member of a
new family of antibacterialsF the ketolidesF and has
been developed speci¢cally to provide optimal therapy
for the treatmentof respiratory infections such as AECB
(6). This agent possesses well-balanced activity against
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including drug-resistant strains (7^12), and has a low
potential for the selection of resistant S. pneumoniae iso-
lates or induction of cross-resistance to other antimicro-
bial agents (13^15). Recently, pharmacokinetic studies
with telithromycin have con¢rmed that a convenient
oral dosage of 800mgonce daily achieves concentrations
in bronchopulmonary tissues and £uids that consistently
exceed theminimum inhibitory concentrations (MICs) of
all relevant respiratory pathogens (16). Taken together,
such ¢ndings indicate that telithromycin represents a
promising new agent for the ¢rst-line empiric treatment
of AECB and other respiratory infections.
The aim of the present study was to evaluate the e⁄-
cacy and safety of a short 5-day course of telithromycin,
800mg once daily, vs. a standard10-day course of amox-
icillin/clavulanate in the treatment of adult patients with
AECB anddocumentedconcomitantchronic obstructive
pulmonary disease (COPD; forced expiratory volume in
1s [FEV1]/forced vital capacity [FVC]o70%).
MATERIALSANDMETHODS
The present randomized, double-blind, parallel-group
study in outpatients with a diagnosis of AECB (with
documented airway obstruction) was conducted
between March1998 and May1999 at 45 centers in eight
countries (Argentina, Australia, Belgium, France, Ger-
many, Republic of Ireland, South Africa, and the U.K.).
Independent ethics committees approved the study in
each country, all patients having provided written in-
formed consent before enrollment. The study was per-
formed in accordance with the latest revisions to the
Declaration of Helsinki.
Study subjects
Adult outpatients (aged 18 years) with a history of
chronic bronchitis and COPD (FEV1/FVCo70%), a
bronchodilator response (with 0.4mg salbutamol)
de¢ned as an increase of o12% from baseline in FEV1
from a lung function test performed within 1 year prior
to inclusion, and a clinical diagnosis of AECB due to pre-
sumed bacterial infection (i.e. increased cough and/or
dyspnea, increased production of sputum, and increased
purulence of sputum) were eligible for inclusion. Patients
with acute bronchitis, pneumonia, asthma, bronchiecta-
sis, cystic ¢brosis, lung cancer, active pulmonary tuber-
culosis, or acute respiratory failure were excluded from
the study, as were pregnant or lactating women (includ-
ing those of childbearing age not using adequate contra-
ception) and patients who had received other
antimicrobials within 7 days prior to enrollment. Addi-
tional exclusion criteria included: need for hospitalization
for parenteral antimicrobial therapy or suspected non-
bacterial respiratory infection; impaired hepatic, renal,or immunologic function; andknown longQT syndrome,
sick sinus syndrome, bradycardia, or severe hypokale-
mia. Patients with suspected or known hypersensitivity
to macrolides or b-lactam antimicrobials and those re-
quiring concomitant treatmentwithmedications known
to have contraindicated interactions with either study
drug were also excluded.
Study design
Patients were assessed at ¢ve separate visits in the pre-
sent study. At the baseline visit (Day 1), patients under-
went a physical examination with assessment of
infection-related signs and symptoms, including a chest
X-ray and lung function tests (if no lung function tests
had been performed within the previous 12 months); a
12-lead electrocardiogram (ECG) was also performed.
Sputum samples were collected for bacteriologic analy-
sis. If an organism was isolated from these samples, the
investigator was to record whether the isolate(s) was
responsible for the current infection. Only pathogens
isolated from adequate sputum (Gram stain showing
25 polymorphonuclear cells and 10 epithelial cells)
were considered responsible. Susceptibility testing was
performed using disk di¡usion methods at local labora-
tories for each individual center involved in the study;
MIC testing was carried out by a central laboratory
(GRMicro Ltd, London,U.K.). Eligible patients were sub-
sequently randomized (1:1) to receive oral treatment
with either telithromycin 800mg once daily for 5 days
or amoxicillin/clavulanate 500/125mg three times daily
for 10 days. A masking technique was used to maintain
blinding, with patients in the telithromycin group receiv-
ing matching placebo for 5 days after completion of the
5-day course of active treatment. Repeat clinic visits
were made on Days 3^5 (on-therapy visit) and Days
11^13 (end-of-therapy visit), when infection-related
signs and symptoms, overall clinical status, compliance
(counting of returned, unused study medication),
and safety/tolerability were assessed. Patients subse-
quently attended a post-therapy test-of-cure (TOC)
visit on Days 17^21 for determination of clinical and
bacteriologic outcome. A follow-up, late post-therapy
visit was also performed (Days 31^36) to determine
any relapse or reinfection and to assess bacteriologic
outcome.
METHODS
E⁄cacy evaluations
The primary e⁄cacy variable was the rate of clinical
cure at the post-therapy TOC visit for the clinical per-
protocol population.The following criteria were used to
assess clinical outcome: infection-related signs and
864 RESPIRATORYMEDICINEsymptoms of AECB, including physical examination
¢ndings speci¢c to the chest and lungs, graded according
to a four-point scale (0^3) of absent, mild, moderate
and severe. At the post-therapy TOC visit, the
investigator was asked if the patient was cured. If he/she
assessed the patient as cured, he/shewas asked to speci-
fy if therewas disappearance or return to the pre-infec-
tion state of AECB-related signs and symptoms, or
persistence of symptoms representing the normal clear-
ance of the in£ammatory process but without the need
for additional antimicrobial therapy (improvement or
post-infectious stigmata). Patientswere classi¢ed as clin-
ical failures if AECB-related signs and symptoms
remained unchanged or had worsened. Other criteria
consistent with clinical failure were the appearance of
new clinical ¢ndings indicating active infection or a
requirement for additional antimicrobial therapy up to
Day 24 of the study. An indeterminate clinical outcome
was assumed for those patients in whom no post-treat-
ment information was available (e.g. because of prema-
ture withdrawal) and for those who received additional
antimicrobial therapy for any indication other than
AECB, pneumonia, or any other lower respiratory tract
infection.
Secondary e⁄cacy variables were clinical cure at the
late post-therapy visit and bacteriologic outcome at the
post-therapyTOC and late post-therapy visits. The bac-
teriologic outcome by subject was computerized, based
on the bacteriologic response by pathogen and categor-
ized as satisfactory or unsatisfactory. A satisfactory bac-
teriologic outcome at the post-therapy TOC visit was
de¢ned as absence (eradication) of the causative patho-
genduring culture ofbacteriologic samples, no additional
antimicrobials having been started prior to sample col-
lection. Patients in whom a follow-up culture was unob-
tainable due to clinical improvement, and who had not
received additional antimicrobials, were also deemed to
have achieved a satisfactory bacteriologic outcome. An
unsatisfactory outcome was recorded if the causative
pathogen was still present (persistence) or was pre-
sumed to be still present (e.g. because of the need for
additional antimicrobials in view of clinical failure), or if a
new pathogen emerged during therapy (superinfection).
Further criteria for recording an unsatisfactory bacter-
iologic outcomewere elimination of the causative patho-
gen followed by its reappearance (recurrence) or
replacement with a new species, serotype, or biotype
(reinfection).
Safety and tolerability
Patientswho received at least one dose of studymedica-
tion and had at least one safety assessment during treat-
ment were evaluable for safety. All adverse events
spontaneously reported by patients and those identi¢edby investigator observation were recorded and evalu-
ated in terms of intensity (mild, moderate, or severe)
and causality to study medication (possibly related or
not related). Laboratory safety parameters and a12-lead
ECG recording were measured at baseline, during, and
on completion of treatment, andwere analyzed for clini-
callyrelevant trends. All ECG traceswere interpretedby
a single independent cardiologist, blinded to treatment
group.
Analysis
Themodi¢ed intent-to-treat (mITT) population included
all patients with a con¢rmed diagnosis of AECB who
received at least one dose of study medication. Those
without major protocol deviations or without an
indeterminate response constituted the clinical per-pro-
tocol population. All patients in the mITT population
were evaluable for bacteriologic outcome provided a
causative pathogen was identi¢ed from pretreatment
samples. The bacteriologic per-protocol population
comprised patients with a causative pathogen identi¢ed
at study entry and who had a satisfactory or unsatisfac-
torybacteriologic response at the post-therapyTOCvis-
it. Patients with an unsatisfactory response before Day
17, and those who had no sample collected at the post-
therapy TOC visit due to clinical resolution, were also
included in the per-protocol analysis of bacteriologic
outcome.
The primary e⁄cacy analysis was to demonstrate
equivalence between the two treatment groups for
clinical cure rates in the clinical per-protocol population
at the post-therapy TOC visit. This was done by
calculating a two-sided 95% con¢dence interval of the
di¡erence in cure rates between the two treatments
(17). Sample sizes (102 subjects per group) were calcu-
lated assuming a cure rate of 85% in each group, conclud-
ing quivalence if the lower boundary of the 95%
con¢dence interval for the di¡erence in cure rates was
15% and the upper boundary was40% (18,19). Sam-
ple size calculation was made at the ¢nalization of the
Clinical Development Plan, following the regulatory
recommendations for antimicrobials available at the
time (20). Between-group di¡erences for continuous
and categoric variables were analyzed using analysis of
variance and Cochran^Mantel^Haenszel methods,
respectively.
RESULTS
A total of 325 patients from eight countries were en-
rolled into the study (Argentina, n=21; Australia, n=21;
Belgium, n=12; France, n=68; Germany, n=51; Ireland,
n=8; South Africa, n=17; U.K. n=127). Of these, 324
were randomized to receive treatment with either teli-
TELITHROMYCINVSAMOXICILLIN/CLAVULANATE INAECB 865thromycin 800mgonce daily for 5 days (n=163) or amox-
icillin/clavulanate 500/125mg three times daily for10 days
(n=161).Threepatients discontinued the studybeforere-
ceiving study treatment (due to withdrawal of consent
[n=3]).The remaining 321patients received at least one
dose of studymedication, although one patient was sub-
sequently excluded because of con¢rmed pneumonia.
The mITT population, therefore, comprised a total of
320 patients (telithromycin, n=160; amoxicillin/clavula-
nate, n=160). The study population was predominantly
male, with a signi¢cant proportion of elderly patients
(65 years; 49.1%). As expected, most patients had a his-
tory of smoking and had experienced 1^4 episodes of
AECB in the previous year.The majority were receiving
chronic therapy with bronchodilators, and 43.4% of pa-
tients had FEV1/FVCo60%. A total of 93 (29.1%) patients
were excluded because of major protocol violations or
indeterminate response, and were similarly distributed
between the two treatmentgroups, leaving 227patients
in the clinical per-protocol population (telithromycin,
n=115; amoxicillin/clavulanate, n=112). Baseline demo-
graphics and disease characteristics of the clinical
per-protocol and mITT populations were comparable,
with no relevant between-group di¡erences (Tables 1
and 2).
Overall, the majority of patients in each treatment
group completed the allocated course of treatment,
with a compliance rate of 93.8%.Of note, the compliance
in the ¢rst 5 days of treatment was higher than in the
total 10 days of treatment, with 89.4% of patients being
100% compliant in the ¢rst 5 days vs. 60.6% in the10-day
treatment course (data on ¢le).TABLE 1. Baseline demographic characteristics (modi¢ed inten
population [PP], n= 227)
Characteristic
Telithromyci
800mgqd for 5
mITT
(n= 160)
Gender, n (%)
Male 93 (58.1)
Female 67 (41.9)
Median (range) age, years 61.5 (18^82)
Aged65 years, n (%) 70 (43.8)
Mean (7SD) bodyweight (kg) 70.5714.2
Smoking status, n (%)
Smoker 67 (41.9)
Ex-smoker 70 (43.8)
Non-smoker 23 (14.4)
Abbreviations: n,Numberof patients; qd, once daily; SD, standarClinical outcome
Among per-protocol patients, the clinical cure rates ob-
tained with telithromycin given once daily for 5 days
were equivalent to those for amoxicillin/clavulanate
given three times daily for 10 days. At the post-therapy
TOC and late post-therapy visits, clinical cure rates for
telithromycin were 86.1 and 78.1%, respectively, com-
pared with 82.1 and 75.0% for amoxicillin/clavulanate.
The 95% con¢dence interval for the between-group
di¡erences con¢rmedequivalencewith amoxicillin/clavu-
lanate (Table 3). Similar ¢ndings were observed for clini-
cal cure rates among the mITT population. Cure rates
were lower for the latter population given that patients
with an indeterminate outcome were rated as clinical
failures (whereas these patients were excluded from the
per-protocol analysis).
Subgroup analysis showed that a high clinical cure rate
was also achieved for patients atgreater riskof complica-
tions, such as the elderly, those with signi¢cant airways
obstruction (i.e. FEV1/FVCo60%) and those with severe
AECB (Fig. 1) with a shorter treatment duration and a
more convenient dosing regimen.
Therewas no di¡erence in treatment e¡ect across in-
vestigator centers (Breslow Day test for homogeneity
not signi¢cant;P=0.486).
Pathogens andbacteriologic outcome
Atbaseline, a total of105 pathogens assessed as causative
for AECB were isolated from 94 (28.9%) patients. The
distribution of causative pathogens was similar for thet-to-treat patient population [mITT], n= 320; per-protocol
Treatmentgroup
n
days
Amoxicillin/clavulanate
500/125mg tid for10 days
PP
(n= 115)
mITT
(n= 160)
PP
(n= 112)
68 (59.1) 104 (65.0) 77 (68.8)
47 (40.9) 56 (35.0) 35 (31.3)
63 (38^82) 66 (22^84) 67.5 (22^83)
52 (45.2) 87 (54.4) 67 (59.8)
70.3713.4 70.8715.7 72.2716.4
51 (44.3) 70 (43.8) 48 (42.9)
49 (42.6) 72 (45.0) 54 (48.2)
15 (13.0) 18 (11.3) 10 (8.9)
d deviation; tid, three times daily.
TABLE 2. Baseline clinical characteristics (modi¢ed intent-to-treat population [mITT], n= 320; per-protocol population [PP],
n= 227)
Characteristic Treatmentgroup
Telithromycin
800 mgqd for 5 days
Amoxicillin/clavulanate
500/125 mg tid for10 days
mITT
(n= 160)
PP
(n= 115)
mITT
(n= 160)
PP
(n= 112)
Duration of current AECB episode, n (%)
1^3 days 53 (33.1) 42 (36.5) 57 (35.6) 46 (41.1)
4^7 days 58 (36.3) 42 (36.5) 59 (36.9) 46 (41.1)
47 days 49 (30.6) 31 (27.0) 44 (27.5) 20 (17.9)
Investigator assessmentof severity, n (%)
Mild 11 (6.9) 7 (6.1) 18 (11.3) 15 (13.4)
Moderate 136 (85.0) 97 (84.3) 123 (76.9) 81(72.3)
Severe 13 (8.1) 11 (9.6) 19 (11.9) 16 (14.3)
FEV/FVC, n (%)a
o60% 69 (43.1) 57 (49.6) 70 (43.8) 59 (52.7)
60^o75% 71 (44.4) 56 (48.7) 65 (40.6) 50 (44.6)
75% 10 (6.3) 2 (1.7) 17 (10.6) 3 (2.7)
Unknown 10 (6.3) F 8 (5.0) F
Numberof AECB episodes in last year, n (%)
0 6 (3.8) 4 (3.5) 15 (9.4) 14 (12.5)
1^4 132 (82.5) 93 (80.9) 124 (77.5) 81 (72.3)
44 21 (13.1) 17 (14.8) 21 (13.1) 17 (15.2)
Unknown 1 (0.6) 1 (0.9) F F
Chronic treatment, n (%)
Bronchodilators 120 (75.0) 85 (73.9) 105 (65.6) 71 (63.4)
Inhaled corticosteroids 52 (32.5) 44 (38.3) 43 (26.9) 38 (33.9)
Oxygen 6 (3.8) 3 (2.6) 9 (5.6) 8 (7.1)
Cyanosis, n (%) 12 (7.5) 12 (10.4) 6 (3.8) 6 (5.4)
Causative pathogens, n
Haemophilus in£uenzae 20 14 21 12
Streptococcus pneumoniae 12 11 8 5
Moraxella catarrhalis 5 4 10 7
Haemophilus parain£uenzae 6 6 1 1
Staphylococcus aureus 2 1 2 2
Pseudomonas aeruginosa 1 1 3 3
Otherb 9 5 5 2
TOTAL 55 42 50 32
Abbreviations:FEV1, forced expiratory volume in s;FVC, forced vital capacity; nnumber of patients or pathogens; qd, once daily;
tid, three times daily.
aPercentage of predictednormalvalue.
bIncluding Acinetobacter spp., Enterobactercloacae,Escherichia coli,Haemophilus spp.,Klebsiella pneumoniae subsp. ozaenae,Neisseria
sicca, Proteus mirabilis, Pseudomonas spp.,Group A streptococci, and Streptococcus mitis.
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H. in£uenzae, S. pneumoniae, M. catarrhalis, andH. parain-
£uenzae (39.0,19.0,14.3 and 6.7% of isolates, respectively).
Bacteriologic outcome among the per-protocol popu-
lation at the post-therapyTOCvisit was satisfactory for
27/39 (69.2%) patientswho received telithromycin and 21/
30 (70.0%) patients treated with amoxicillin/clavulanate.
Similar results were observed for the mITT population
(30/50 [60.0%] and 25/44 [56.8%] patients, respectively).Eradication rates at the post-therapyTOC visit for bac-
teriologically evaluable patients are summarized for the
per-protocol population inTable 4. The overall eradica-
tion rates for the telithromycin and amoxicillin/clavula-
nate treatment groups were 76.2 and 81.3%,
respectively.Corresponding values for themITTpopula-
tionwere 36/48 (75.0%) and 35/43 (81.4%), respectively.
Five cases of persistence were documented among
telithromycin recipients at the post-therapy TOC visit
TABLE 3. Clinicalcureratesin adultpatients treatedwitheither telithromycinoramoxicillin/clavulanate foracuteexacerbation
of chronic bronchitis, according to patientpopulation and timing of assessment
Telithromycin
800mgqd for 5 days
n (%)
Amoxicillin/clavulanate
500/125 mg tid for10 days
n (%)
Di¡erence
(95% CI)
Post-therapy test-of-cure (Days17^21)
Per-protocol 99/115 (86.1) 92/112 (82.1) 4.0% (6.4%,14.3%)
Modi¢ed intent-to-treat 130/160 (81.3) 125/160 (78.1) 3.2% (6.3%,12.6%)
Late post-therapy (Days 31^36)
Per-protocol 82/105 (78.1) 81/108 (75.0) 3.1% (9.2%,15.4%)
Modi¢ed intent-to-treat 118/160 (73.8) 114/160 (71.3) 2.5% (7.9%,12.9%)
Abbreviations: n, numberof patients;CI, con¢dence interval; n, numberof patients; qd, once daily; tid, three times daily.
FIG. 1. Clinical cure rates in adult patients treated with either
telithromycin or amoxicillin/clavulanate for acute exacerbation
of chronic bronchitis (AECB): per-protocol population and sub-
groupsof specialinterest.Abbreviations:FEV1, forcedexpiratory
volumein1s;FVC, forcedvital capacity; qd, once daily; tid, three
times daily.
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four further cases of presumed persistence (S. pneumo-
niae, n=1; H. in£uenzae, n=3) and one case of recur-
rence (H. parain£uenzae). Among those who received
amoxicillin/clavulanate, four cases of documentedpersis-
tence (Staphylococcus aureus, n=1; Hafnia alvei, n=1;
Pseudomonas aeruginosa, n=2), one case of presumed
persistence (S. pneumoniae) and one case of recurrence
(H. parain£uenzae) were noted at the post-therapyTOC
visit. There were no cases of superinfection during the
study. More reinfections were identi¢ed in the amoxicil-
lin/clavulanate group comparedwith thosewho received
telithromycin (9 vs 2; mITT population).
At the late post-therapy visit, the rates of successful
bacteriologic outcome and eradicationwere comparable
for the two treatment groups (data not shown).Atypical pathogens
Aminor proportion of patients in each treatment group
was infected with atypical pathogens that were consid-
ered causative for AECB [Chlamydophila (Chlamydia)
pneumoniae, Mycoplasma pneumoniae]. Atypical infec-
tionswere diagnosed if thepatienthad a negative aerobic
culture for any ‘typical’ pathogen and the following strin-
gent criteria were met: clinical signs and symptoms of
AECB in association with a 4-fold increase in IgG
(C. pneumoniae, M. pneumoniae) or IgM (C. pneumoniae)
titers between acute and convalescent sera. All patients
with a positive diagnosis of C. pneumoniae infection
achieved a clinical outcome of cure (2/2 for telithromy-
cin; 2/2 for amoxicillin/clavulanate). No M. pneumoniae
infections were diagnosed.
Tolerability
A total of 320 patients were evaluable for safety (teli-
thromycin, n=160; amoxicillin/clavulanate, n=160).
Overall, both treatments were generally well tolerated,
with 97 (30.3%) patients reporting at least one treat-
ment-emergent adverse event (telithromycin, n=38
[23.8%]; amoxicillin/clavulanate, n=59 [36.9%]). The be-
tween-group di¡erence for frequency of treatment-
emergent adverse events was statistically signi¢cant
(P=0.015).Themost commonly reported adverse events
involved the gastrointestinal system (Table 5), and were
generally of mild to moderate intensity.Overall, the fre-
quency of adverse events possibly related to the study
drug (investigator assessment)was almost two-foldhigh-
er in the amoxicillin/clavulanategroup (Table 5), compris-
ing diarrhea, dyspepsia, and vomiting.Discontinuation of
treatment as a result of adverse events was also lower
for telithromycin recipients (1.9 vs. 10.0% of amoxicillin/
clavulanate-treatedpatients).Themostcommonreasons
for treatment discountinuation were diarrhea, nausea,
and vomiting.
TABLE 4. Bacteriologic eradication ratesa (post-therapy test-of-cure visit;Days17^21) for adult patients treatedwith either teli-
thromycin or amoxicillin/clavulanate for acute exacerbation of chronic bronchitis (per-protocolpopulation)
Pathogen Telithromycin
800 mgqd for 5 days
n (%)
Amoxicillin/clavulanate
500/125 mg tid for10 days
n (%)
Haemophilus in£uenzae 7/14 (50.0) 12/12 (100)
Streptococcus pneumoniae 10/11 (90.9) 4/5 (80.0)
Haemophilus parain£uenzae 5/6 (83.3) 0/1 (0)
Moraxella catarrhalis 4/4 (100) 7/7 (100)
Staphylococcus aureus 1/1 (100) 1/2 (50.0)
Pseudomonas aeruginosa 1/1 (100) 1/3 (33.3)
Otherb 4/5 (80.0) 1/2(50.0)
Total 32/42 (76.2) 26/32 (81.3)
aDocumented andpresumed eradication.
bIncluding Enterobactercloacae,Haemophilus spp.,Neisseria sicca, Proteus mirabilis, and Pseudomonas spp.
Abbreviations: n, numberof pathogens; qd, once daily; tid, three times daily.
TABLE 5. Summaryoftreatment-emergent adverse events (TEAEs) reported by2% of patients in either treatmentgroup
Adverse event Telithromycin
800mgqd for 5 days
(n= 160) n (%)
Amoxicillin/clavulanate 500/125 mg tid for10 days
(n= 160), n (%)
Diarrhea 5 (3.1) 16 (10.0)
Bronchitis 2 (1.3) 12 (7.5)
Dyspepsia 1 (0.6) 5 (3.1)
Vomiting 1 (0.6) 5 (3.1)
Totalno. of patientswithTEAEs 38 (23.8)* 59 (36.9)
Possiblyrelated to studydrug 21 (13.1) 40 (25.0)
Abbreviations: n, numberof patients; qd, once daily; tid, three times daily.
*P= 0.015 vs. amoxicillin/clavulanate.
868 RESPIRATORYMEDICINEThirteen (4.1%) patients experienced serious treat-
ment-emergent adverse events (telithromycin, n=7
[4.4%]; amoxicillin/clavulanate, n=6 [3.8%]). With the
exception of a severe gastrointestinal disorder (abdom-
inal pain, vomiting, and diarrhea) in one patient treated
with amoxicillin/clavulanate (which resolved following
appropriate treatment), no serious adverse event was
considered drug-related. There were no deaths during
the study and no apparent between-group di¡erences in
terms of vital signs, ECG ¢ndings, or laboratory safety
parameters.
DISCUSSION
The ¢ndings of the present study with telithromycin,
a new ketolide antibacterial, show that a short
5-day course of treatment (800mg once daily) is at least
as e¡ective as a standard 10-day course of amoxicillin/
clavulanate for the treatment of adult patients with
AECB.A number of antimicrobial agents are currently used
to treat AECB, of which amoxicillin/clavulanate is fre-
quently prescribed.Use of this agent is appropriate given
that H. in£uenzae is one of most commonly isolated
pathogens in AECB (2,21) and that b-lactam resistance
(via b-lactamase production) among such isolates is
increasing (22).However, S. pneumoniae is also frequently
implicated in AECB (2,21), with resistance to b-lactams
increasing at an alarming rate (4,22,23). Given that the
resistance mechanism involves alteration of penicillin-
binding proteins, isolates of S. pneumoniae with reduced
susceptibility to penicillin also show decreased suscept-
ibility to amoxicillin/clavulanate (22).The utility of alter-
native antimicrobials is also being hampered by the
emergence of drug-resistant strains. Macrolides, for
example, show no activity against erythromycin-resis-
tant strains of S. pneumoniae and have decreased activity
against strains with reduced pencillin susceptibility
(9,10,22). The emergence of strains with decreased sus-
ceptibility to £uoroquinolones is also of increasing con-
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These limitations in the bacteriologic spectrum of exist-
ing agents, coupled with the need for multiple daily dos-
ing in some instances (which can lead to poor
compliance) (24), highlight the need for new agents that
are not only e¡ective against the broad range of likely
pathogens in AECB, including resistant strains, but
which also have convenient dosage regimens.
In this study, amoxicillin/clavulanate at the recom-
mendeddosage of 500/125mg three times daily was cho-
sen as the comparator treatment in view of its proven
e⁄cacy in the ¢rst-line empiric treatment of respiratory
infections such as AECB.This equivalence was observed
in a population of subjects carefully selected at entry: all
the subjects in this trial had a documented obstruction
on lung function test andmet three criteria of exacerba-
tion (increased cough and/or dyspnea, increased produc-
tion of sputum, and increased purulence of sputum).The
¢ndings for telithromycin are comparable with those
reported for other antimicrobials used in the treatment
of AECBwith or without COPD, including cephalospor-
ins and macrolides. For example, several authors have
reported an overall clinical cure or improvement rate of
84% for ceftibuten (25,26), 90% for azithromycin (27),
and 87% for clarithromycin (26). A clinical cure rate of
86.1% for short-course telithromycin therapy also com-
pares favorably with reported ¢ndings for £uoroquino-
lones (28^31).Unlike the present study, inclusion criteria
in most of these trials did not include documented
obstruction or three criteria of exacerbation. The pro-
mising ¢ndings of the present study have since been con-
¢rmed in another comparative clinical trial of
telithromycin in the treatment of AECB, in which a
5-day course of telithromycin 800mg once daily was as
e¡ective as 10 days’ treatment with cefuroxime axetil
(data on ¢le).
As anticipated, H. in£uenzae and S. pneumoniae were
the pathogens most commonly isolated in this study.
Overall, 60.0% of patients in the mITT population who
received telithromycin achieved a satisfactory bacterio-
logic outcome at the post-therapy TOC visit compared
with 56.8% of patients treated with amoxicillin/clavula-
nate, increasing to 69.2 and 70.0%, respectively, in the
per-protocol population.These ¢ndings were paralleled
by rates of successful bacteriologic eradication of the
common respiratory pathogens in the telithromycin and
amoxicillin/clavulanate treatment groups, with overall
eradicationrates of 76.2 and 81.3%, respectively, although
the relatively low numbers for each pathogen make it
somewhatdi⁄cult to drawconclusions.Overall, the bac-
teriologic outcome and eradication rates for telithromy-
cin are similar to those reported in AECB patients
treatedwith a variety of existing antimicrobials (32,33).
An important ¢nding of the present study was that a
short course of treatment with telithromycin, namely
800mg once daily for 5 days, was as e¡ective (clinicallyand bacteriologically) as a standard10-day regimenwith
amoxicillin/clavulanate. Indeed, the value of shorter
courses of antimicrobial therapy is being increasingly
recognized in terms of promoting good patient compli-
ance, which is pivotal not only for ensuring an optimal
response to treatment, but also in terms of minimizing
conditions that favor the emergence of drug resistance.
The issue of compliance is particularly relevant in the
elderly, for whompolypharmcy is common (34). Overall,
high levels of compliance were observed for both treat-
ment groups in the present study, although compliance
with a three times daily regimen of amoxicillin/clavula-
nate outside of the controlled clinical trial environment
may be considerably lower.This is also suggested by the
comparison of compliance in the ¢rst 5 days of treatment
compared with the10-day treatment in this study.With
the convenience of once-daily administration and a short
5-day course of treatment, telithromycin is expected to
result in better compliance when used in patients with
AECB.
Atypical organisms such asM. pneumoniae andC. pneu-
moniae are relatively infrequent causes of AECB (21).
Indeed, no infections due to M. pneumoniae were diag-
nosed and only a small number of patients had infections
with C. pneumoniae in the present study. Overall, teli-
thromycin achieved clinical cure in all such patients,
which canbe explainedbyhigh levels of drug penetration
into the tissues and £uids of the respiratory tract,
including alveolar macrophages (16). The high clinical
rates for amoxicillin/clavulanate in patients with AECB
caused by C. pneumoniae were unexpected, although si-
milar ¢ndings have been reported by other authors (35)
and raise doubts on the causality of atypical pathogens in
the exacerbation itself.
Prompt diagnosis and appropriate treatment are par-
ticularly important in high-risk patientswith AECB, such
as the elderly, those with severe airways obstruction,
and patients with severe symptoms. Analysis of these
patient subgroups in the present study found that the
two treatments were similarly e⁄cacious in terms of
clinical cure. Interestingly, there was a trend towards a
higher rate of clinical cure among telithromycin-treated
patients with severe AECB, although the number of eva-
luable patients is too small to draw conclusions.
Both treatments were well tolerated in the present
study. Overall, the tolerability pro¢le of telithromycin
was consistentwith that reported in other studies of pa-
tients with respiratory infections (6, 36^38). Adverse
events were typically mild to moderate in intensity, and
were generally gastrointestinal in nature.Notably, there
was a signi¢cantly lower incidence of adverse events and
fewer withdrawals due to tolerability concerns among
patients treated with telithromycin. In terms of optimiz-
ing patient compliance, such ¢ndings may complement
the convenience of a short course of once-daily therapy
with this agent.
870 RESPIRATORYMEDICINEIn conclusion, a convenient treatment regimen of teli-
thromycin 800mg once daily for 5 days appears to be at
least as e¡ective and well tolerated as amoxicillin/clavu-
lanate (500/125mg three times daily for 10 days) in the
treatment of AECB in adults with COPD.
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